Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
-
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
-
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
-
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at ATC 2024
-
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
-
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
-
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
-
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
-
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
-
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)